1-20 of 46
Lorenz Truemper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper
Journal: Blood
Blood (2021) 138 (Supplement 1): 135.
https://doi.org/10.1182/blood-2021-145124
Published: 2021
Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Clinical Trials & Observations
Norbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, Marita Ziepert, Mathieu Leclerc, Guillaume Cartron, Arnaud Jaccard, Peter Reimer, Eva Wagner, Martin Wilhelm, Laurence Sanhes, Thierry Lamy, Laurence de Leval, Andreas Rosenwald, Muriel Roussel, Frank Kroschinsky, Walter Lindemann, Peter Dreger, Andreas Viardot, Noël Milpied, Christian Gisselbrecht, Gerald Wulf, Emmanuel Gyan, Philippe Gaulard, Jacques Olivier Bay, Bertram Glass, Viola Poeschel, Gandhi Damaj, David Sibon, Alain Delmer, Karin Bilger, Anne Banos, Mathias Haenel, Martin Dreyling, Bernd Metzner, Ulrich Keller, Friederike Braulke, Birte Friedrichs, Maike Nickelsen, Bettina Altmann, Olivier Tournilhac
Journal: Blood
Blood (2021) 137 (19): 2646–2656.
https://doi.org/10.1182/blood.2020008825
Published: 2021
Includes: Supplemental data
Journal Articles

Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA)

Fabian Frontzek, MD, Marita Ziepert, PhD, Maike Nickelsen, Bettina Altmann, PhD, Bertram Glass, Mathias Haenel, MD, Lorenz Truemper, MD PhD, Gerhard Held, MD, Martin Bentz, MD, Peter Borchmann, MD, Martin Dreyling, MD, Andreas Viardot, Professor Dr, Frank P. Kroschinsky, MDMBA, Bernd Metzner, MDPhD, Annette M. Staiger, PhD, Heike Horn, PhD, German Ott, MD, Andreas Rosenwald, MD, Markus Loeffler, MD, Georg Lenz, Norbert Schmitz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-138412
Published: 2020
Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, Owen A. O'Connor, MD, Barbara Pro, MD, Tim Illidge, MD PhD, Swami P. Iyer, MD, Ranjana Advani, MD, Nancy L. Bartlett, MD, Jacob Haaber Christensen, Franck Morschhauser, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, MD, Won Seog Kim, PhD, Tatyana A. Feldman, MD, Tobias Menne, MD PhD, David Belada, MD PhD, Árpád Illés, MD PhD, Kensei Tobinai, MD, Kunihiro Tsukasaki, MD PhD, Su-Peng Yeh, MD, Andrei R Shustov, MD, Andreas Hüttmann, MD, Kerry J. Savage, BSc, MD MSc, Sam Yuen, MBBS, FRACP, FRCPA, Pier Luigi Zinzani, MD, Harry Miao, MD, Veronica Bunn, PhD, Keenan Fenton, MA, Michelle A. Fanale, MD, Markus Puhlmann, MD, Lorenz Truemper, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-134398
Published: 2020
Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Kerry J Savage, BSc, MD MSc, Steven M. Horwitz, MD, Ranjana H Advani, MD, Jacob H. Christensen, MD, Eva Domingo-Domenech, MD, Giuseppe Rossi, Franck Morschhauser, MD, Onder Alpdogan, MD, Cheolwon Suh, Kensei Tobinai, MD PhD, Andrei R Shustov, MD, Marek Trneny, MD prof, Sam Yuen, MBBS,FRCPA,FRACP, Pier Luigi Zinzani, MD PhD, Lorenz Truemper, MD, Timothy Illidge, MD PhD, Owen O'Connor, MD PhD, Barbara Pro, MD, Meredith Little, MPH, Veronica Bunn, Keenan Fenton, Thomas Manley, MD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 464.
https://doi.org/10.1182/blood-2019-122781
Published: 2019
Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, Ajibade O Ashaye, MD MBA, MPH, MSc., Ruchit Shah, PhD, Shelby Corman, PharmD, MS, BCPS, Mehul Dalal, PhD, Lorenz Truemper, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3482.
https://doi.org/10.1182/blood-2019-127289
Published: 2019
Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Fabian Frontzek, MD, Marita Ziepert, PhD, Maike Nickelsen, Bettina Altmann, PhD, Bertram Glass, Mathias Hänel, MD, Lorenz Truemper, MD, Gerhard Held, MD, Martin Bentz, MD, Peter Borchmann, MD, Martin H. Dreyling, MD PhD, Andreas Viardot, MD PhD, Frank P. Kroschinsky, MDMBA, Bernd Metzner, MD PhD, Annette M. Staiger, PhD, Heike Horn, PhD, German Ott, MD, Andreas Rosenwald, MD, Markus Loeffler, MD, Georg Lenz, MD, Norbert Schmitz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1589.
https://doi.org/10.1182/blood-2019-123637
Published: 2019
Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2877.
https://doi.org/10.1182/blood-2019-128021
Published: 2019
Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Florian Zettl, Friederike Braulke, Marita Ziepert, PhD, Andreas Viardot, MD PhD, Christoph Kahl, MD, Gabriele Prange-Krex, Agnieszka Korfel, Martin H. Dreyling, MD PhD, Thomas Illmer, MD, Josef Birkmann, MD, Ulrich Wedding, Dietmar Reichert, Maike de Wit, MD, Frank Hartmann, MD, Hans-Juergen Hurtz, Norbert Schmitz, MD, Mathias Witzens-Harig, MD, Wolfram Klapper, Andreas Rosenwald, MD, Viola Poeschel, MD, Markus Loeffler, MD, Gerald Wulf, MD, Bettina Altmann, PhD, Lorenz Truemper, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4073.
https://doi.org/10.1182/blood-2019-122948
Published: 2019
Journal Articles

Radioimmunotherapy for Mantle Cell Lymphoma: 5-Year Follow-up of 90 Patients from the International RIT-Registry

Karin Hohloch, Christine Windemuth-Kieselbach, Pier Luigi Zinzani, MD PhD, Roberto E. Cacchione, MD, Wojciech Jurczak, MD PhD, Cheolwon Suh, Lorenz Truemper, MD, Christian W Scholz
Journal: Blood
Blood (2019) 134 (Supplement_1): 5263.
https://doi.org/10.1182/blood-2019-124192
Published: 2019
Journal Articles

A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

Annette M. Staiger, PhD, Michael Altenbuchinger, PhD, Marita Ziepert, PhD, Christian Kohler, PhD, Heike Horn, Michael Huttner, Katrin Huettl, MD, Wolfram Klapper, MD, Monika Szczepanowski, PhD, Julia Richter, PhD, Andreas Rosenwald, Harald Stein, MD PhD Dr. h.c., Alfred Feller, Peter Moeller, MD, Martin-Leo Hansmann, Markus Loeffler, MD, Viola Poeschel, MD, Gerhard Held, MD, Lorenz Truemper, MD, German Ott, MD, Rainer Spang, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 343.
https://doi.org/10.1182/blood-2018-99-112450
Published: 2018
Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 998.
https://doi.org/10.1182/blood-2018-99-110429
Published: 2018
Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Viola Poeschel, MD, Gerhard Held, MD, Marita Ziepert, PhD, Bettina Altmann, PhD, Mathias Witzens-Harig, MD, Harald Holte, MD PhD, Lorenz Thurner, MD, Andreas Viardot, MD, Peter Borchmann, MD, Lothar Kanz, Ulrich Keller, Christian Schmidt, MD, Rolf Mahlberg, MD, Bernd Metzner, MDPhD, Reinhard Marks, Heinz-Gert Hoeffkes, MD, Konstantinos Christofyllakis, MD, Josif Amam, Christian Berdel, MD, Stephan Stilgenbauer, Norbert Schmitz, MD, Lorenz Truemper, MD, Niels Murawski, MD, Markus Loeffler, MD, Michael Pfreundschuh, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 781.
https://doi.org/10.1182/blood-2018-99-112403
Published: 2018
Journal Articles

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Bettina Altmann, PhD, Gerald Wulf, MD, Lorenz Truemper, MD, Francesco d'Amore, MD, Thomas Relander, Helle Toldbod, MS,PhD, Jan M.A. Delabie, MD PhD, Andreas Rosenwald, Marita Ziepert, PhD, Markus Loeffler, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1622.
https://doi.org/10.1182/blood-2018-99-112076
Published: 2018
Journal Articles

Excellent Outcome of Elderly Patients with Favourable-Prognosis DLBCL Treated with 4 Cycles CHOP/Chlip-14 Plus 8 Applications of Rituximab and a PET-Based Intensification Strategy That Includes Involved-Site Radiotherapy (IS-RT): Results of the First 120 Patients of the OPTIMAL>60 Trial of the Dshnhl

Michael Pfreundschuh, MD, Niels Murawski, MD, Konstantinos Christofyllakis, Bettina Altmann, Marita Ziepert, PhD, Mathias Haenel, MD, Andreas Viardot, MD, Andreas Neubauer, MD, Gerhard Held, MD, Lorenz Truemper, Christian Schmidt, MD, Lothar Kanz, Kai Huebel, MD, Norbert Schmitz, MD, Tobias Heintges, MD, Heinz Kirchen, MD, Günther Schneider, MD, Christian Ruebe, MD, Christian Berdel, MD, Dirk Hellwig, MD, Jirka Grosse, MD, Viola Poeschel, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1549.
https://doi.org/10.1182/blood.V130.Suppl_1.1549.1549
Published: 2017
Journal Articles

Acquisition Patterns and Interaction of Molecular, Obvious and Cryptic Cytogenetic Abnormalities in Myelodysplastic Syndromes

Christina Ganster, Katayoon Shirneshan, Sascha Dierks, Roman Martin, Bertram Glass, Haifa Kathrin Al-Ali, Michael Metz, Ulrich Germing, MD, Uwe Platzbecker, MD, Nicolaus Kroeger, Friederike Braulke, Julie Schanz, Lorenz Truemper, Detlef Haase
Journal: Blood
Blood (2017) 130 (Supplement 1): 4260.
https://doi.org/10.1182/blood.V130.Suppl_1.4260.4260
Published: 2017
Journal Articles

Exosome Mediated Wnt-Signaling Augments Side Population In Aggressive Lymphoma

Raphael Koch, Martin Demant, Thiha Aung, Annemarie Guentsch, Nina Diering, Bjoern Chapuy, MD, PhD, Lorenz Truemper, Gerald Wulf, MD
Journal: Blood
Blood (2013) 122 (21): 3010.
https://doi.org/10.1182/blood.V122.21.3010.3010
Published: 2013
Journal Articles

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Simone Ferrero, Alessandro Pastore, Roswitha Forstpointner, M.D., Christian W. Scholz, Antonio Pezzutto, Lothar Bergmann, Lorenz Truemper, Juergen Finke, Ulrich Keller, Marco Ladetto, Wolfgang Hiddemann, M.D., Oliver Weigert, Michael Unterhalt, Martin Dreyling
Journal: Blood
Blood (2013) 122 (21): 4384.
https://doi.org/10.1182/blood.V122.21.4384.4384
Published: 2013
Journal Articles

TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20 + Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial

Thorsten Zenz, MD, Markus Kreuz, Doris Winter, Hanne Helfrich, Maxi Fuge, Heike Horn, MD, Julia Richter, PhD, Reiner Siebert, Lorenz Truemper, MD, Norbert Schmitz, MD, Markus Loeffler, Wolfram Klapper, Andreas Rosenwald, MD, Hartmut Döhner, MD, Michael Pfreundschuh, MD, German Ott, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2012) 120 (21): 546.
https://doi.org/10.1182/blood.V120.21.546.546
Published: 2012
Journal Articles

Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Eva Hoster, Dr., Michael Unterhalt, Dr., Bernd Metzner, Michael Pfreundschuh, MD, Peter Staib, Georg Jacobs, Hans Walter Lindemann, Wolf-Dieter Ludwig, H. Tilman Steinmetz, Lorenz Truemper, Hannes Wandt, Christian Buske, Martin H. Dreyling, PhD, Wolfgang Hiddemann, PhD
Journal: Blood
Blood (2011) 118 (21): 1639.
https://doi.org/10.1182/blood.V118.21.1639.1639
Published: 2011